Vanda Announces Listing of a New Fanapt® Patent in the FDA Orange Book

Sep 23, 2015, 16:30 ET from Vanda Pharmaceuticals Inc.

WASHINGTON, Sept. 23, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a Fanapt® patent, number 9,138,432 ('432 patent), is now listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book.  As described in the Orange Book, this patent covers a method of treating schizophrenia by administering Fanapt® to a patient by reducing the dose in patients who are also being treated with the antidepressant fluoxetine.  The '432 patent was issued by the United States Patent and Trademark Office in September 2015 and expires in September 2025. 

Prior to this newly listed patent, the Fanapt® Orange Book listed patents were the U.S. composition of matter '198 patent, the '610 patent, the '776 patent, the '638 patent, the '742 patent, the '254 patent, the '255 patent, and the '256 patent expected to expire in November 2016, November 2027, August 2030, October 2030, January 2031, December 2031, December 2030, and February 2031 respectively.

About Vanda Pharmaceuticals Inc. 
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. For more on Vanda, please visit www.vandapharma.com.

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
Various statements in this release are "forward-looking statements" under the securities laws. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, Vanda's assumptions regarding the life of the Fanapt® patents and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2014 and quarterly report on Form 10-Q for the quarter ended June 30, 2015, which are on file with the SEC and available on the SEC's website at www.sec.gov. In addition to the risks described above and in Vanda's annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

Corporate Contact:
Jim Kelly
Senior Vice President and Chief Financial Officer 
Vanda Pharmaceuticals Inc.  
(202) 734-3428
jim.kelly@vandapharma.com 

Media Contact:
Laney Landsman 
Vice President 
Makovsky 
(212) 508-9643 
llandsman@makovsky.com

SOURCE Vanda Pharmaceuticals Inc.



RELATED LINKS

http://www.vandapharma.com